CTN Bulletin logo
May 12, 2021

Webinar: Meth 2.0 and Opioid Use Disorder: A Collision of Epidemics



Larissa MooneyJoin the Western States Node and the Northwest and Pacific Southwest ATTCs on May 25 (11am-12:30pm PT) for a webinar featuring Greater Southern California Node co-PI Larissa Mooney, MD.

The goal of the NIDA Clinical Trials Network and Addiction Technology Transfer Center (ATTC) webinar series is to help scholars and clinicians in the addiction field stay abreast of cutting edge science.

In this session, Dr. Mooney will discuss recent trends in co-occurring methamphetamine use and opioid use disorder (OUD), including overdose fatalities. Participants will also learn about the treatment approaches to address this rising comorbidity.

Learning objectives

  1. Recall at least two recent epidemiological trends in co-occurring methamphetamine use and opioid use disorder.
  2. Identify at least three medical risks of co-occurring methamphetamine and opioid use.
  3. Explain at least three evidence-based treatment approaches that can be utilized with patients who use both methamphetamine and opioids.


Please note: You must select the type of credits you would like to receive on the registration form; this information cannot be modified later. No partial credits will be granted -- you must attend the full live webinar to qualify.

Download flyer | CME Information | REGISTER HERE!

CTN Trial Progress

GraphRandomizations for Active Studies as of the May 11 trial Progress Report.

CTN-0060-A-1 - Enrolled 541

CTN-0069 - Enrolled 757

CTN-0079-A-1 - Enrolled 14   

CTN-0080 - Enrolled 47

CTN-0082 - Enrolled 345

CTN-0097 - Enrolled 43

CTN-0099 - Enrolled 349

CTN-0099-A-1 - Enrolled 75

CTN-0101 - Enrolled 9 

This project is supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute, but the information on this site has not been reviewed by NIDA and does not necessarily reflect the views of the Institute.

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

Are You Presenting About the CTN? The CTN Dissemination Library Wants Your Slides!

presentation slides on laptop and screenSpring and summer are big times of year for conferences! If you're presenting about CTN-related work at any upcoming (or past!) events, the CTN Library would love to have a copy of your slides or poster to add to the collection!

Submit your slides to us at ctnlib@uw.edu and have a great conference season!

Some upcoming events:

  • Society for Prevention Research (SPR)
    June 2-4, 2021 | Meeting info

  • International Cannabinoid Research Society
    June 20-25, 2021| Meeting info

  • College on Problems of Drug Dependence (CPDD)
    June 21-24, 2021 | Meeting info
    The NIDA International Forum will be held in conjunction with CPDD | Meeting info

  • International AIDS Society (IAS) AIDS 2021
    July 18-21, 2021 | Meeting info

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

News from the Nodes

Appalachian Node

Appalachian node logoDuring a recent Appalachian Node Listening Tour, community partners indicated that protecting harm reduction services (e.g., syringe services programs, naloxone distribution) continues to be critical for limiting community transmission of HIV and viral hepatitis. Despite community and expert opposition, the West Virginia legislature passed SB 334 that places severe restrictions on syringe services that may result in many closures among the 16 existing programs.

Dr. Feinberg, multi-PI of the Appalachian Node, worked with a dedicated group of community advocates, physicians, and public health experts to provide testimony against the bill and to convince Gov. Justice to veto it, but it was signed into law on April 15. This will be very problematic as West Virginia has HIV outbreaks in its two largest cities, Charleston and Huntington, as well as scattered cases around the state, and a tremendous burden of hepatitis B (#1 in the U.S. for acute cases), hepatitis C (#1 or #2 in the U.S. for acute cases, depending on the year) and overdose fatalities (#1 in the U.S. for a decade).

The Appalachian Node recently launched their Quarterly Newsletter. Please email Appalachian.Node@pitt.edu to sign up for the mailing list.

Greater Intermountain

Adam GordonCongratulations to Adam Gordon, MD, MPH, recipient of the 2020 HSR&D Health System Impact Award! This award honors HSR&D- and QUERI-funded research that has had a direct and important impact on clinical practice or clinical policy within the VA health care system -- and that has been successfully translated into VA’s policy or operations. Read more about Dr. Gordon and the award here!

Western States

Appalachian node logoThe Western States Node, in partnership with the Big Southwest Node, is offering an Addiction Sciences webinar series for established and early career health services investigators. The series is held on the third Monday of each month at 11:00AM PST.

Our next speaker will be Dr. Noel Vest who will be talking about "Latent Class and Growth Mixture Modeling with CTN (and other) Longitudinal Data." Join via this Zoom link.


Greater Southern California

Appalachian node logoCongratulations to Sarah Clingan and Zhe Fei!

Sarah Clingan, PhD, and Zhe Fei, PhD, are receiving the 2021 CPDD Early Career Investigator Award.

Dr. Clingan is a postdoctoral research fellow at UCLA Integrated Substance Abuse Programs (ISAP) working with Drs. Yih-Ing Hser and Larissa Mooney.

At CPDD, she will present on the impact of COVID-19 on the delivery of medication treatment for opioid use disorder from the perspective of substance use treatment providers.

Dr. Fei is an Assistant Professor In-Residence in the Biostatistics Department at UCLA. At CPDD, he will present on the impact of complex comorbidity conditions on survival of opioid use disorder patients.

Post-doctoral position: UCLA and Greater Southern California Node

The UCLA Integrated Substance Abuse Programs (ISAP) seeks a full time post-doctoral position who is in interested in interdisciplinary research on SUD topics, with an emphasis on experimental clinical trials to develop and test effective treatments for SUDs, especially opioid use disorder.

Duration of the fellowship is flexible, initially for one year, with possible extension. Salary will be commensurate with experience and capabilities.

The candidate will join a highly productive research team at UCLA including the CTN Greater Southern California Node, UCLA ISAP, and work with UCLA researchers and investigators on numerous clinical trials on SUD treatment, focus on blending clinical practice and research, as well as learn skills in advanced methodologies applicable to clinical trials.

Interested individuals should send a cover letter, CV, and contact information for three references to Yih-Ing Hser, Ph.D. (yhser@mednet.ucla.edu) and Larissa Mooney, M.D. (lmooney@mednet.ucla.edu).

UCLA is an equal opportunity/affirmative action employer.

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

New in the CTN Dissemination Library

The 2021 CTN Directory is here! Download your copy today! (You can also find this linked on the CTN Dissemination Library home page under "About the CTN.")

Hser Y, et al. Is Telemedicine the Answer to Rural Expansion of Medication Treatment for Opioid Use Disorder? Early Experiences in the Feasibility Study Phase of a National Drug Abuse Treatment Clinical Trials Network Trial [commentary]. Addiction Science & Clinical Practice 2021;16:24. (CTN-0102)

Greiner MG, et al. Naturalistic Follow-Up After a Trial of Medications for Opioid Use Disorder: Medication Status, Opioid Use, and Relapse. Journal of Substance Abuse Treatment 2021;131:108447. (CTN-0051)

Tai B, et al. The NIDA Clinical Trials Network: Evolving, Expanding, and Addressing the Opioid Epidemic. Addiction Science & Clinical Practice 2021;16:28.

Murphy SM, et al. Cost-Effectiveness Implications of Increasing the Efficiency of the Extended-Release Naltrexone Induction Process for the Treatment of Opioid Use Disorder: A Secondary Analysis. Addiction 2021 (in press). (CTN-0051)

· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·

From the ATTC Network

ATTC Messenger - May 2021
The Power We Hold [as healthcare providers]. By Sandeep Kapoor, MD, Northwell Health

New SAMHSA Resource
Advisory: Opioid Therapy in Patients with Chronic Noncancer Pain Who Are in Recovery from Substance Use Disorders

ATTC/NIATx Service Improvement Blog
Behavioral Health Resources for Service Members and Veterans (National Military Appreciation Month)

Call for Proposals

Addiction Health Services Research (AHSR) 2021
October 13-15, 2021

Submit your virtual poster; top-rated posters will be invited for brief oral presentations.
Information here

NIDA in the News
Why New Guidelines for Opioid Treatment are a "Big Deal." Audie Cornish, NPR, April 27, 2021, featuring Nora Volkow, NIDA Director.


Published by the CTN Dissemination Library of the Pacific Northwest Node
Addictions, Drug & Alcohol Institute, University of Washington

This project is supported by a grant from the National Institute on Drug Abuse to the University of Washington Addictions, Drug & Alcohol Institute, but the information on this site has not been reviewed by NIDA and does not necessarily reflect the views of the Institute.

Unsubscribe | Subscribe